

National Cancer Institute and GSK present the latest updates on Immuno-Oncology at 4th annual Cancer Vaccines gathering

SMI's 4th annual Cancer Vaccines conference takes place on 16th and 17th September 2015 in Central London

LONDON, ENGLAND, UNITED KINGDOM, August 11, 2015 /EINPresswire.com/ -- From biomarkers in oncology and developments in clinical trials, through to fully personalised cancer treatments and new therapeutic interventions, SMI's [Cancer Vaccines](#) conference will gather an array of immuno-oncology experts from around the world to share their knowledge on advancing cancer immunotherapies when it returns to London next month.

Conference Highlights Include:

- A focus on immunotherapies: Some of the topics discussed on immunotherapy include multi-model cancer immunotherapy, oncolytic virotherapy, immune response in DNA vaccinations and gene editing for immunotherapy.

- Personalised RNA immunology: Dr Kreiter recently took part in the pioneering development of actively personalized cancer vaccination. His presentation entitled: RNA - Vaccinology: From Ware-Houses to Actively Personalized Cancer Vaccines, will discuss simulating tumour-specific antigen recognition with a focus on epitope design of multi-antigen tumour vaccines and neo-antigens. His interview is available to read in the event [download centre](#).

“

...the program is very comprehensive and picks up the hot topics

*BioNTech RNA
Pharmaceuticals*

- A GSK Vaccines case study: Recent research has enabled the design of adjuvants which can optimise and boost the quality of a vaccine. Hear more on advancing the next

generations of adjuvants in a presentation by the Global Head of Vaccine Chemistry and Formulation from GSK Vaccines, Derek O'Hagan. The presentation will explore the impact of delivery on adjuvants with a focus on formulation and particle size.

- Drinks Reception: Lead sponsors Northwest Biotherapeutics will host a networking drinks reception on the evening of Day One. Some of those who have confirmed attendance at the event include: Biosafe SA, Boehringer Ingelheim, Exicure Inc, Immunicum, Intellicyt, National Cancer Institute, Northwest Biotherapeutics Inc, Plymouth University, Roche, Shionogi Limited, St Georges Hospital Medical School, Theravectys, TRON Translational Oncology Mainz and University Of Pennsylvania



Already creating a buzz in the industry, here's what some of the attendees said about what presentations they were looking forward to hearing at Cancer Vaccines 2015.

"All of them! But in particular the provocative talk that will be given by Michael G. Hanna, Jr. Founder & Chairman Emeritus, Vaccinogen, Inc" - Dr. Stéphanie McArdle, Senior Research Scientist in Tumour Immunology, Nottingham Trent University

"The session on RNA vaccine, because I believe it is very promising technology to induce a powerful CD8 T cell response." - Ugo D'oro, Head of Immunology, GSK Vaccines

"..getting the big pharma viewpoint on combination immuno-oncology. I'm also keen to hear about the immuno-oncologists' current opinion regarding individualised cellular cancer immunotherapy." - Thomas Felzmann, Associate Professor of Immunology and CEO, Activartis Biotech GmbH

"Since the program is very comprehensive and picks up the hot topics it is hard to choose. For sure I am looking forward to the talks addressing tumor heterogeneity and combination therapies." - Sebastian Kreiter, VP of Immunotherapy, BioNTech RNA Pharmaceuticals

For further details, visit the website at www.cancervaccinesevent.com

Interviews with key speakers, are available to read in the event download centre

Cancer Vaccines 2015

New frontiers in targeted immuno-therapies to achieve sustained immune response

16 - 17 Sept 2015

Marriott Regents Park, London, UK

www.cancervaccinesevent.com

Sponsored by Northwest Biotherapeutics and Intellicyt

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.